CanSino Biologics launches new H share option scheme for employee incentives

CanSino Biologics Inc. has adopted the "2025 H Share Option Scheme" to enhance its incentive mechanisms and promote continuous business growth. The scheme targets core management personnel, including Xuefeng Yu, Tao Zhu, Shou Bai Chao, and Dongxu Qiu. The board has resolved to grant a total of 860,000 options, with each option entitling the holder to subscribe for one H share.

The options will vest in three tranches: 40% at the first anniversary of the grant date, 30% at the second, and 30% at the third. Vesting is conditional on the company achieving specific performance targets for financial years 2025 to 2027, related to operating revenue growth and the number of approved INDs/NDAs.

The maximum number of shares available under the scheme and all other share schemes is 3,440,000 H shares, representing approximately 1.39% of the total H shares in issue as of the adoption date. Individual participants cannot exceed 1% of the total shares in issue within a 12-month period without separate shareholder approval. The scheme will be valid for 48 months from the adoption date.